The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.

NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

Intellia Therapeutics Inc (NTLA) stock saw a modest uptick, ending the day at $9.5 which represents a slight increase of $0.08 or 0.85% from the prior close of $9.42. The stock opened at $9.48 and ...

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.

Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...

The biotech said it has dosed the first participant in a Phase 3 study of its in vivo gene editing treatment. Elsewhere, the FDA imposed a hold on Atara and lifted another on Amylyx.

Intellia Therapeutics, Inc. announced the dosing of the first patient in the global Phase 3 study for NTLA-2002, a CRISPR-based therapy aimed at treating hereditary angioedema (HAE). This ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) shares acquire momentum first thing. The Cambridge, Mass.-based Intellia, a leading clinical-stage gene editing company focused on revolutionizing medicine ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Intellia ...

Intellia Therapeutics has dosed the first subject in a randomised, placebo-controlled global Phase III trial of its investigational CRISPR-based therapy, NTLA-2002, to treat hereditary angioedema ...